Management paradigms for metastatic non–small cell lung cancer (mNSCLC) are evolving.
Locally ablative therapies are now being increasingly integrated into combined-modality …

Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer
with comparable local control rates to surgical resection. Owing to the conformity of …

Rearrangements in anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule-
associated protein-like 4 (EML4) gene were first described in a small portion of patients with …

In recent years, many personalized treatments have been developed for NSCLC (non-small-
cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective …

Background Pemetrexed is approved in the treatment of advanced stage nonsquamous non–
small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to …

Background Randomized phase III trials showed interesting, but conflicting results,
regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all …

The fusion of echinoderm microtubule-associated protein-like 4 with the anaplastic
lymphoma kinase (EML4-ALK) is found in 3%–7% of non-small-cell lung cancer (NSCLC) …

Purpose Published data on the clinical efficacy, safety, dosage and administration, and costs
of the anaplastic lymphoma kinase (ALK) inhibitors crizotinib and ceritinib in the treatment of …

Background: With advances such as next-generation sequencing (NGS) increasing
understanding of the basis of cancer and its response to treatment, NCCN believes it is …

The functions of different regulatory T cell (Treg) types in cancer progression are unclear.
Recently, expression of the transcription factor Helios was proposed as a marker for natural …